The past week has been tough on the stocks of major medtech companies, which, like many, are figuring out how to manage the global trade war.

Cala today announced new results from multiple clinical studies further expanding the body of evidence for its TAPS therapy.

Hologic (Nasdaq: HOLX) announced that it appointed Wayde McMillan to its board of directors, effective April 4, 2025.

ICU Medical (Nasdaq: ICUI) today announced new regulatory milestones that open up a new category for its infusion systems.

Johnson & Johnson MedTech‘s  Medical announced today that it initiated a study evaluating its Javelin coronary IVL catheter.